Galecto (GLTO) News Today $5.84 +0.03 (+0.52%) (As of 10:25 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Galecto (NASDAQ:GLTO) Shares Down 5.3% - Should You Sell?November 19 at 2:33 AM | americanbankingnews.comGalecto (NASDAQ:GLTO) Stock, Option ChainNovember 15, 2024 | benzinga.comGalecto, Inc. Announces Strategic Shift and Financial OverviewNovember 2, 2024 | markets.businessinsider.comGalecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and OpportunitiesNovember 2, 2024 | tipranks.comGalecto reports Q3 EPS ($3.39) vs ($7.50)November 1, 2024 | msn.comGalecto Reports Third Quarter 2024 Financial ResultsNovember 1, 2024 | globenewswire.comGalecto price target raised to $10 from $9 at OppenheimerOctober 18, 2024 | finance.yahoo.comGalecto incorpora a la Dra. Amy Wechsler a su Consejo de AdministraciónOctober 17, 2024 | es.investing.comOppenheimer Sticks to Its Buy Rating for Galecto (GLTO)October 17, 2024 | markets.businessinsider.comGalecto (NASDAQ:GLTO) Price Target Increased to $10.00 by Analysts at OppenheimerOppenheimer raised their price target on shares of Galecto from $9.00 to $10.00 and gave the stock an "outperform" rating in a research note on Thursday.October 17, 2024 | marketbeat.comGalecto Strengthens Board of Directors with Appointment of Dr. Amy WechslerOctober 15, 2024 | globenewswire.comGalecto To Focus On Clinical Stage Compound GB1211; Obtains Global Rights To BRM-1420October 7, 2024 | markets.businessinsider.comWhy Galecto (GLTO) Shares Are Down 27% TodayOctober 7, 2024 | msn.comGalecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge MedicinesOctober 7, 2024 | globenewswire.comLas acciones de Galecto tocan un máximo de 52 semanas a 11,67 USD en medio de las fluctuaciones del mercadoAugust 31, 2024 | es.investing.comGalecto Announces Reverse Stock SplitAugust 28, 2024 | globenewswire.comMinerva Neurosciences Inc (4MNA.BE)July 19, 2024 | finance.yahoo.comGLTO Stock Earnings: Galecto Beats EPS for Q1 2024May 3, 2024 | investorplace.comGalecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with PembrolizumabMay 1, 2024 | globenewswire.com6 Stocks Positioned to Soar as Investors Focus on MASHApril 22, 2024 | theglobeandmail.comGLTO Stock Earnings: Galecto Beats EPS for Q4 2023March 15, 2024 | msn.comGalecto Inc.February 16, 2024 | thestreet.comGalecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?February 14, 2024 | finance.yahoo.comWhat Makes Galecto, Inc. (GLTO) a New Strong Buy StockJanuary 9, 2024 | finance.yahoo.comGalecto, Inc.: Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with MyelofibrosisDecember 23, 2023 | finanznachrichten.deNike, AAR And 3 Stocks To Watch Heading Into FridayDecember 22, 2023 | msn.comTopline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with MyelofibrosisDecember 21, 2023 | finance.yahoo.comGalecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 TrialOctober 23, 2023 | finance.yahoo.comGalecto (GLTO) Price Target Increased by 13.16% to 5.48October 5, 2023 | msn.comGalecto, Inc.: Galecto Announces Plans to Explore Strategic AlternativesOctober 2, 2023 | finanznachrichten.deHC Wainwright & Co. Downgrades Galecto (GLTO)September 30, 2023 | msn.comWeeks after dropping lung disease drug, Galecto lays off most of staff, explores saleSeptember 27, 2023 | bizjournals.comGalecto Announces Plans to Explore Strategic AlternativesSeptember 26, 2023 | finance.yahoo.comGalecto Biotech Collapse: Opportunity For Galectin TherapeuticsSeptember 14, 2023 | msn.comGalecto to Present at Investor Conferences in SeptemberAugust 31, 2023 | finance.yahoo.comHC Wainwright & Co. Maintains Galecto (GLTO) Buy RecommendationAugust 22, 2023 | msn.comExpert Ratings for GalectoAugust 21, 2023 | markets.businessinsider.comBiotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & MoreAugust 17, 2023 | finance.yahoo.comGalecto Ends Development of Lead Candidate After IPF Study Failure >GLTOAugust 16, 2023 | marketwatch.comGalecto (GLTO) Down 71% as Lung Disease Candidate FailsAugust 16, 2023 | finance.yahoo.comSVB Leerink Downgrades Galecto (GLTO)August 15, 2023 | msn.comGalecto shares plummet after biotech drops lung disease drugAugust 15, 2023 | bizjournals.comWhy Is Galecto Stock Plummeting Today?August 15, 2023 | msn.comGalecto to drop lung disease drug after Phase 2 setbackAugust 15, 2023 | seekingalpha.comGalecto to discontinue development of lung disease treatmentAugust 15, 2023 | reuters.comGalecto: Phase 2b Trial Of GB0139 In Idiopathic Pulmonary Fibrosis Fail To Meet Main Goal;stock DownAugust 15, 2023 | markets.businessinsider.comGalecto shares drop 65% as biotech halts development of lung-disease treatmentAugust 15, 2023 | msn.comGalecto Shares Sink to New Lows After Lead Drug Candidate Scrapped >GLTOAugust 15, 2023 | marketwatch.comGalecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary FibrosisAugust 15, 2023 | finance.yahoo.comTrading was temporarily halted for "GLTO" at 09:08 AM with a stated reason of "LULD pause."August 15, 2023 | marketbeat.com Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin GLTO Media Mentions By Week GLTO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLTO News Sentiment▼0.580.47▲Average Medical News Sentiment GLTO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLTO Articles This Week▼20▲GLTO Articles Average Week Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RenovoRx News Today Surrozen News Today BioVie News Today Lantern Pharma News Today BioLineRx News Today HCW Biologics News Today Citius Pharmaceuticals News Today KALA BIO News Today Daré Bioscience News Today Pluri News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLTO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
